Edwards Lifesciences Co. (NYSE:EW) Given Consensus Rating of “Hold” by Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have been given a consensus rating of “Hold” by the twenty-six analysts that are presently covering the stock, MarketBeat reports. Sixteen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $78.65.

Several research firms have recently commented on EW. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Truist Financial restated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Citigroup upped their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,000 shares of company stock worth $2,323,150. 1.29% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Lantz Financial LLC increased its stake in Edwards Lifesciences by 25.3% in the 2nd quarter. Lantz Financial LLC now owns 3,236 shares of the medical research company’s stock valued at $299,000 after buying an additional 654 shares during the period. Blue Trust Inc. increased its stake in shares of Edwards Lifesciences by 38.2% in the second quarter. Blue Trust Inc. now owns 5,051 shares of the medical research company’s stock worth $483,000 after acquiring an additional 1,397 shares during the last quarter. Raymond James & Associates raised its holdings in shares of Edwards Lifesciences by 2.8% during the second quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock worth $168,597,000 after acquiring an additional 50,124 shares in the last quarter. Williams Financial LLC acquired a new stake in Edwards Lifesciences during the second quarter valued at $201,000. Finally, Raymond James Financial Services Advisors Inc. grew its stake in Edwards Lifesciences by 0.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 1,154,757 shares of the medical research company’s stock valued at $106,665,000 after purchasing an additional 10,176 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.9 %

Shares of Edwards Lifesciences stock opened at $73.32 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $69.42 and a 200 day moving average price of $73.99. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a market cap of $43.24 billion, a P/E ratio of 10.58, a P/E/G ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the business earned $0.59 EPS. The business’s quarterly revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts forecast that Edwards Lifesciences will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.